Sarepta Therapeutics, Inc. Uncategorized Contracts & Agreements
54 Contracts & Agreements
- Additional Call Option Transaction Confirmation, dated as of September 14, 2022 between Sarepta Therapeutics, Inc. and RBC Capital markets, LLC (Filed With SEC on September 19, 2022)
- Additional Call Option Transaction Confirmation, dated as of September 14, 2022 between Sarepta Therapeutics, Inc. and Morgan Stanley & Co. LLC (Filed With SEC on September 19, 2022)
- Additional Call Option Transaction Confirmation, dated as of September 14, 2022 between Sarepta Therapeutics, Inc. and Mizuho Markets Americas LLC (Filed With SEC on September 19, 2022)
- Additional Call Option Transaction Confirmation, dated as of September 14, 2022 between Sarepta Therapeutics, Inc. and Goldman Sachs & Co. LLC (Filed With SEC on September 19, 2022)
- Additional Call Option Transaction Confirmation, dated as of September 14, 2022 between Sarepta Therapeutics, Inc. and Barclays Bank PLC (Filed With SEC on September 19, 2022)
- Base Call Option Transaction Confirmation, dated as of September 13, 2022, between Sarepta Therapeutics, Inc. and RBC Capital Markets, LLC (Filed With SEC on September 19, 2022)
- Base Call Option Transaction Confirmation, dated as of September 13, 2022, between Sarepta Therapeutics, Inc. and Morgan Stanley & Co. LLC (Filed With SEC on September 19, 2022)
- Base Call Option Transaction Confirmation, dated as of September 13, 2022, between Sarepta Therapeutics, Inc. and Mizuho Markets Americas LLC (Filed With SEC on September 19, 2022)
- Base Call Option Transaction Confirmation, dated as of September 13, 2022, between Sarepta Therapeutics, Inc. and Goldman Sachs & Co. LLC (Filed With SEC on September 19, 2022)
- Base Call Option Transaction Confirmation, dated as of September 13, 2022, between Sarepta Therapeutics, Inc. and Barclays Bank PLC (Filed With SEC on September 19, 2022)
- Letter Agreement, dated April 19, 2022, between Sarepta Therapeutics, Inc. and Douglas S. Ingram (Filed With SEC on April 21, 2022)
- Offer Letter dated March 17, 2017 by and between Sarepta Therapeutics, Inc. and Joseph Bratica (Filed With SEC on March 1, 2021)
- Offer Letter dated by December 18, 2014 and between Sarepta Therapeutics, Inc. and Ian M. Estepan (Filed With SEC on March 1, 2021)
- Promotion Letter dated December 14, 2020 by and between Sarepta Therapeutics, Inc. and Ian M. Estepan (Filed With SEC on March 1, 2021)
- Offer Letter dated April 19, 2018 by and between Sarepta Therapeutics, Inc. and Louise Rodino-Klapac (Filed With SEC on March 1, 2021)
- Promotion Letter dated December 14, 2020 by and between Sarepta Therapeutics, Inc. and Louise Rodino-Klapac (Filed With SEC on March 1, 2021)
- Description of Registered Securities (Filed With SEC on February 26, 2020)
- Letter Agreement between Sarepta Therapeutics, Inc. and Myonexus Therapeutics, Inc. dated February 26, 2019 (Filed With SEC on May 8, 2019)
- Letter Agreement between Douglas S. Ingram and Sarepta Therapeutics, Inc. dated June 26, 2018 (Filed With SEC on August 8, 2018)
- First Amendment to Sponsored Research Agreement between AVI BioPharma, Inc. and Charleys Fund, Inc. dated June 2, 2009 (Filed With SEC on May 3, 2018)
- Sponsored Research Agreement between AVI BioPharma, Inc. and Charleys Fund, Inc., effective October 12, 2007 (Filed With SEC on May 3, 2018)
- Additional Call Option Transaction Confirmation, dated as of November 9, 2017, between Sarepta Therapeutics, Inc. and Goldman Sachs & Co. LLC (Filed With SEC on November 14, 2017)
- Additional Call Option Transaction Confirmation, dated as of November 9, 2017, between Sarepta Therapeutics, Inc. and JPMorgan Chase Bank, National Association, London Branch (Filed With SEC on November 14, 2017)
- Base Call Option Transaction Confirmation, dated as of November 8, 2017, between Sarepta Therapeutics, Inc. and Goldman Sachs & Co. LLC (Filed With SEC on November 14, 2017)
- Base Call Option Transaction Confirmation, dated as of November 8, 2017, between Sarepta Therapeutics, Inc. and JPMorgan Chase Bank, National Association, London Branch (Filed With SEC on November 14, 2017)
- Letter Agreement by and between Sarepta Therapeutics, Inc. and Catherine Stehman-Breen dated September 26, 2017 (Filed With SEC on November 1, 2017)
- Letter Agreement by and between Sarepta Therapeutics, Inc. and Guriqbal S. Basi dated September 25, 2017 (Filed With SEC on November 1, 2017)
- Offer Letter dated August 28, 2017 by and between Sarepta Therapeutics, Inc. and Guriqbal S. Basi (Filed With SEC on November 1, 2017)
- Offer Letter dated February 2, 2017 by and between Sarepta Therapeutics, Inc. and Dr. Catherine Stehman-Breen (Filed With SEC on May 4, 2017)
- Offer Letter dated December 3, 2012 by and between Sarepta Therapeutics, Inc. and Alexander Bo Cumbo (Filed With SEC on May 4, 2017)
- Offer Letter dated December 5, 2012 by and between Sarepta Therapeutics, Inc. and Shamim Ruff (Filed With SEC on May 4, 2017)
- [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. (Filed With SEC on August 9, 2016)
- 15B, SUPPLIES/SERVICES (Filed With SEC on November 7, 2012)
- 3. EFFECTIVE DATE 13-Apr-2011 (Filed With SEC on August 8, 2011)
- 11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS (Filed With SEC on May 10, 2011)
- 3450 MonteVilla Parkway, Suite 101, Bothell, WA 98021 ** 425 ###-###-#### ** FAX: 425 ###-###-#### (Filed With SEC on March 15, 2011)
- AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT (Filed With SEC on May 10, 2010)
- SETTLEMENTAGREEMENT (Filed With SEC on April 22, 2010)
- AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT (Filed With SEC on November 9, 2009)
- FIRST AMENDMENT TO SPONSORED RESEARCHAGREEMENT (Filed With SEC on August 10, 2009)
